Zydus Lifesciences has expanded its companion diagnostics portfolio with the launch of Diasens and GlucoLive, next-generation continuous glucose monitoring devices that combine artificial intelligence, real-time data streaming and integrated remote-care capabilities for patients with diabetes, chronic kidney disease and post-transplant needs. Designed to provide continuous glycaemic surveillance, the system aims to move glucose monitoring in India beyond episodic finger-prick tests and occasional lab checks, towards a closed-loop ecosystem that connects patients, caregivers and clinicians in real time.
The new CGM platform is built around an integrated AI layer that analyses glucose data and feeds actionable insights to both patients and clinicians. Readings are automatically streamed to the patient’s smartphone every three minutes without the need for manual scanning, in contrast to most existing CGM devices in India that rely on NFC technology and require patients to scan the sensor to retrieve data. By eliminating these manual steps, the system is intended to ensure uninterrupted data capture, including overnight and during emergencies, reduce gaps in monitoring and enable earlier clinical intervention.
Zydus has partnered with Digicare Health Solutions (TatvaCare) to integrate the CGM system with TatvaCare’s GoodFlip app, which serves as a digital hub for the companion diagnostics offering. Through GoodFlip, patients will gain access to AI-powered report analysis, personalised diet and exercise coaching, doctor consultations, diagnostic lab booking and a consolidated medical record vault within a single mobile application. The app’s analytics engine is designed to detect trends, flag hypo- and hyperglycaemic episodes, link fluctuations to food and activity, and generate insights that can support more precise treatment adjustments.
On the clinician side, a dedicated remote-monitoring dashboard will allow healthcare providers to track glucose patterns, identify high-risk episodes and intervene earlier, potentially reducing complications in complex chronic conditions. By integrating cardiology, nephrology, hepatology, urology, oncology and transplant care within the same data environment, the company positions Diasens and GlucoLive as tools that can support multidisciplinary management rather than stand-alone devices.
Announcing the launch in Bengaluru on 12 March 2026, Dr Sharvil Patel, Managing Director, Zydus Lifesciences, said the new devices represent a strategic strengthening of the company’s chronic disease portfolio. “The launch of Diasens and GlucoLive strengthens our companion diagnostics portfolio for chronic disease management. Focused on patient-centric convenience and better quality of life, these CGMs powered by AI technology, will give patients real-time access to key glycaemic data on their mobile devices, simplifying monitoring and control,” he said. He added that “the convergence of science, innovation, health and technology is critical for patients managing chronic diseases like diabetes, CKD, or organ transplant – offering a quick, reliable, and safe glucose monitoring solution with utmost convenience.”
The launch comes against the backdrop of a steep metabolic disease burden in India. More than 101 million adults in the country live with diabetes, the second-highest burden globally, and an additional 136 million are in the pre-diabetic stage, according to the ICMR-INDIAB study published in The Lancet Diabetes & Endocrinology. Diabetes is also the leading cause of chronic kidney disease in India, with 25–40 per cent of CKD patients having a history of diabetes. Each year, an estimated 200,000 patients require kidney transplants and 25,000 require liver transplants, with many developing new-onset diabetes due to immunosuppressive therapy.
Yet glucose monitoring for most patients remains intermittent, typically limited to finger-prick tests or HbA1c measurements every three to six months. This pattern leaves large blind spots in daily glucose control, particularly for high-risk groups such as advanced CKD and post-transplant patients. By streaming data every few minutes and linking it with AI-driven analytics, Diasens and GlucoLive are positioned to help close these gaps and support more proactive care.
With its new CGM-based companion diagnostics offering, Zydus is betting on a model where hardware, software and clinical decision-support tools are tightly integrated. The company is framing the launch as part of a broader shift towards technology-enabled chronic disease management, in which continuous data, remote monitoring and personalised coaching are used to improve outcomes in a population facing escalating rates of diabetes, kidney disease and transplant-related metabolic complications.
